Rallybio Corporation
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RLYB research report →
Companywww.rallybio.com
Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody which is in Phase II clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload.
- CEO
- Stephen Uden
- IPO
- 2021
- Employees
- 15
- HQ
- New Haven, CT, US
Price Chart
Valuation
- Market Cap
- $76.64M
- P/E
- -10.53
- P/S
- 89.32
- P/B
- 1.64
- EV/EBITDA
- -1.26
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 99.65%
- Op Margin
- -3278.21%
- Net Margin
- -911.07%
- ROE
- -14.39%
- ROIC
- -55.77%
Growth & Income
- Revenue
- $858.00K · 34.91%
- Net Income
- $-8,978,000 · 84.46%
- EPS
- $-1.59 · 85.06%
- Op Income
- $-28,064,000
- FCF YoY
- 39.51%
Performance & Tape
- 52W High
- $15.31
- 52W Low
- $2.16
- 50D MA
- $10.15
- 200D MA
- $6.51
- Beta
- -1.10
- Avg Volume
- 337.95K
Get TickerSpark's AI analysis on RLYB
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 19, 26 | ADAR1 Capital Management, LLC | buy | 200 |
| May 19, 26 | ADAR1 Capital Management, LLC | buy | 10,000 |
| May 18, 26 | ADAR1 Capital Management, LLC | buy | 6,009 |
| May 15, 26 | ADAR1 Capital Management, LLC | buy | 200 |
| May 15, 26 | ADAR1 Capital Management, LLC | buy | 100 |
| May 13, 26 | ADAR1 Capital Management, LLC | buy | 75,178 |
| May 13, 26 | ADAR1 Capital Management, LLC | buy | 4,081 |
| May 12, 26 | ADAR1 Capital Management, LLC | buy | 800 |
| May 11, 26 | ADAR1 Capital Management, LLC | buy | 19,900 |
| May 11, 26 | ADAR1 Capital Management, LLC | buy | 25,000 |
Our RLYB Coverage
We haven't published any research on RLYB yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate RLYB Report →